Aptorum Group

About:

Aptorum Group is a pharmaceutical company dedicated to the development of therapeutic assets to treat diseases with unmet medical needs.

Website: http://www.aptorumgroup.com/

Top Investors: Aenco Technologies

Description:

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, it is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

Total Funding Amount:

$23.6M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2010-01-01

Contact Email:

investor.relations(AT)aptorumgroup.com

Founders:

Ian Huen

Number of Employees:

11-50

Last Funding Date:

2022-12-09

IPO Status:

Public

Industries:

© 2025 bioDAO.ai